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Abstract
There are still important gaps in our understanding of how people will incorporate PrEP into their existing HIV prevention 
strategies. In this paper, we explore how PrEP use impacted existing sexual risk behaviours and risk reduction strategies 
using qualitative data from the PROUD study. From February 2014 to January 2016, we conducted 41 in-depth interviews 
with gay, bisexual and other men who have sex with men (GBMSM) enrolled in the PROUD PrEP study at sexual health 
clinics in England. The interviews were conducted in English and were audio-recorded. The recordings were transcribed, 
coded and analysed using framework analysis. In the interviews, we explored participants’ sexual behaviour before joining the 
study and among those using or who had used PrEP, changes to sexual behaviour after starting PrEP. Participants described 
the risk behaviour and management strategies before using PrEP, which included irregular condom use, sero-sorting, and 
strategic positioning. Participants described their sexual risk taking before initiating PrEP in the context of the sexualised use 
of drugs, geographical spaces linked with higher risk sexual norms, and digitised sexual networking, as well as problematic 
psychological factors that exacerbated risk taking. The findings highlight that in the main, individuals who were already 
having frequent condomless sex, added PrEP to the existing range of risk management strategies, influencing the boundaries 
of the ‘rules’ for some but not all. While approximately half the participants reduced other risk reduction strategies after 
starting PrEP, the other half did not alter their behaviours. PrEP provided an additional HIV prevention option to a cohort of 
GBMSM at high risk of HIV due to inconsistent use of other prevention options. In summary, PrEP provides a critical and 
necessary additional HIV prevention option that individuals can add to existing strategies in order to enhance protection, 
at least from HIV. As a daily pill, PrEP offers protection in the context of the sex cultures associated with sexualised drug 
use, digitised sexual applications and shifting social norms around sexual fulfilment and risk taking. PrEP can offer short or 
longer-term options for individuals as their sexual desires change over their life course offering protection from HIV during 
periods of heightened risk. PrEP should not be perceived or positioned in opposition to the existing HIV prevention toolkit, 
but rather as additive and as a tool that can and is having a substantial impact on HIV.
Keywords Pre-exposure prophylaxis · PrEP · HIV prevention · Risk compensation · Sexual risk behaviour · Gay and other 
MSM · UK
Introduction
In 2012, the Food and Drug Administration (FDA) approved 
 Truvada® (tenofovir disoproxil fumarate and emtricitabine) 
as the first HIV pre-exposure prophylaxis (PrEP) drug, 
based primarily on evidence from three placebo controlled 
trials [1–4]. The concern about sexual risk compensation 
or disinhibition has accompanied the development of new 
HIV prevention technologies over the last 20 years, and was 
highlighted in the reflection paper issued by the European 
Medicines Agency [5, 6]. Initially, the concern was that a 
reduction in condom use in response to the uptake of par-
tially effective options such as medical male circumcision, 
vaccines and microbicides, could lead to an increase in HIV 
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exposure and consequently acquisition [5, 7]. As confidence 
in the biological efficacy of PrEP has increased, there is 
concern that a reduction in condom use could lead to an 
increase in STI acquisition and related STI drug resistance.
At the time of the FDA approval, there was no evidence 
of risk compensation in the reviewed trials [8, 9]. However, 
in placebo controlled trials participants did not know if 
they were using PrEP or if PrEP was effective and there-
fore would be unlikely to change their behaviours. As such, 
there were unanswered questions about the potential for risk 
compensation when people were using PrEP knowing it was 
efficacious against HIV acquisition. In order to support PrEP 
availability in England, the PrEP e-group, formed in 2011 
of community members, healthcare providers, policy mak-
ers and researchers, recommended a randomised open label 
wait-listed trial design [10]. By randomising participants to 
an immediate start of PrEP or a deferred start of PrEP after 
12 months, the trial design allowed for a robust assessment 
of differences in sexual behaviour and STIs between PrEP 
and non-PrEP users.
The PROUD (PRe-exposure Option for reducing HIV in 
the UK: immediate or Deferred) trial demonstrated that the 
inclusion of PrEP in the sexual health package offered to gay, 
bisexual and other men who have sex with men (GBMSM) 
and trans women, reduced HIV acquisition by 86%, with 
no infections among participants taking PrEP at the likely 
time of exposure [11]. The offer of PrEP in the PROUD 
trial attracted a high-risk group of GBMSM evidenced at 
baseline by high numbers of condomless sex partners (with 
condomless sex being an eligibility criteria) and two-thirds 
of participants reporting an STI in the previous 12 months, 
and during follow up by an HIV incidence of 9 per 100 
persons years in the control group [11, 12]. The PROUD 
trial did not attract trans-women, with only three enrolling, 
probably due to limitations of the recruitment strategy.
In the main trial analysis, although there were no differ-
ences between the groups in terms of most sexual behaviour, 
a larger proportion of participants allocated to the immediate 
PrEP than to the deferred PrEP group reported receptive 
condomless anal sex with ten or more partners. Despite this, 
there was no statistically significant difference between the 
groups for STIs overall, after adjusting for the difference in 
the number of STI screens during the first year of follow 
up [11]. The conclusion from the trial was that among high 
risk GBMSM reporting regular condomless sex, the offer 
of PrEP dramatically reduced HIV acquisition, and did not 
impact on STIs despite a suggestion of lower condom use 
among a small proportion of PrEP users.
PrEP is now available in over 20 countries globally and 
implementation programmes are increasing across Europe. 
While PrEP is available as standard of care in Scotland and 
Wales, it is currently only available for free through par-
ticipation in the Public Health England PrEP Impact trial in 
England, or via private purchase. While the benefit of PrEP 
as a HIV prevention method is clear, there are still gaps in 
our understanding of how people incorporate PrEP into their 
existing HIV prevention strategies. In this paper, we explore 
how PrEP use impacted existing sexual risk behaviours and 
risk reduction strategies using qualitative data from the 
PROUD study.
Methods
PROUD was a pragmatic open-label wait-listed randomised 
controlled trial designed to evaluate the effectiveness of 
daily oral Truvada as HIV PrEP. Recruitment took place 
from November 2012 to April 2014 at 13 sexual health clin-
ics in England, eight in London and five outside of London. 
Eligibility criteria included HIV negative GBMSM or trans-
women, aged 18 or above, who reported condomless anal sex 
in the last 90 days and expected to have it again in the next 
90 days. At enrolment, eligible participants were randomised 
1:1 to receive PrEP immediately or after a deferred period 
of 12 months. Participants were asked to attend the clinic 
quarterly for at least 2-years. The study design, baseline 
characteristics of the cohort and results have been reported 
elsewhere [11, 12].
From February 2014 to January 2016, we planned to pur-
posefully sample up to 50 study participants to take part 
in semi-structured in-depth interviews (IDIs). We aimed to 
select 44 participants based on trial arm allocation (immedi-
ate or deferred), changes in their self-reported risk behav-
iour since enrolment (increased risk or same/decreased risk), 
and self-reported PrEP adherence among participants in 
the immediate group (high or low). From September 2015, 
we amended the selection criteria slightly in an attempt to 
identify more variability by risk behaviour, thereby select-
ing participants based on self-reported current risk behav-
iour instead of changes since enrolment (high risk or low/
medium risk). In addition to the six selection categories we 
aimed to purposefully select approximately six individuals 
to explore under-represented topics.
Researchers who were independent of the study clinic 
team conducted the IDIs. The IDIs lasted on average 
between 45 and 60 mins and participants were not com-
pensated for their time. The IDI guide included a discus-
sion topic on sexual risk behaviour, as well as perceptions, 
experiences and usage of PrEP. Participants provided written 
informed consent and the IDIs were conducted in English 
and were audio-recorded. The recordings were transcribed, 
coded and analysed using framework analysis in NVivo 10 
[13]. The first author coded the interviews, each interviewer 
reviewed the coding of a sub-sample of their interviews, and 
coding discrepancies were discussed. In the results section, 
we present quotes that illustrate the key findings and identify 
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participants by selection criteria (trial arm, risk behaviour, 
if on PrEP by adherence), whether they had used PrEP by 
the time of the interview, whether they were enrolled in a 
clinic in or out of London, and the age group there were in 
at enrolment.
The PROUD study protocol was approved by Lon-
don Bridge Research Ethics Committee, the Medicines 
and Healthcare Products Regulatory Agency and each of 
the 12 participating Hospital Trusts (see list in acknowl-
edgments). The trial is registered with ISRCTN (Number 
ISRCTN94465371) and ClinicalTrials.gov (NCT02065986). 
The study protocol, including participant information sheet 
(PIS) and informed consent form (ICF), and the in-depth 
interview PIS, ICF and interview guide, are available on the 
study website (www.proud .mrc.ac.uk).
Results
We interviewed a total of 41 study participants. Thirty-eight 
were selected equally from the immediate and deferred con-
trol groups. We conducted three additional interviews to 
explore under-represented topics, one with a trans woman, 
another with a person who sero-converted during the study, 
and another with a person who decided not to start PrEP 
(Fig. 1). By the time of interview, 33 participants told us 
they were or had been using PrEP. Thirty participants had 
been prescribed PrEP in the trial, although two had stopped 
using it by the time of the interview. A further three had 
accessed PrEP privately, one by using the Truvada from PEP 
and another using Truvada from a HIV-positive partner both 
during the deferred period, and a third who had purchased it 
in the USA and used it before joining the trial. Participants 
had used PrEP for a mean of 14.3 months by the time of the 
interview, ranging from one week to 32.8 months. Due to 
high adherence across the study cohort, we were unable to 
interview the planned numbers of participants who reported 
low adherence. We interviewed participants from five clinics 
in London, as well as clinics in Sheffield, Manchester and 
Brighton. We present the baseline demographic and sexual 
behaviour profile of the participants who were interviewed 
in Tables 1 and 2.   
In the interviews, we explored participants’ sexual behav-
iour before joining the study and among those using or who 
had used PrEP, changes to sexual behaviour after starting 
PrEP. Below we present data on three key themes: risk 
behaviour and management strategies before using PrEP, 
the contexts within which risk taking occurs, and the impact 
of PrEP on sexual behaviours.
Risk Behaviour and Management Strategies Before 
Using PrEP
All participants recognised they were taking risks that 
potentially exposed them to HIV. A few participants under-
estimated the risk of the behaviour they reported and many 
rationalised their risk taking:
“Here I am quantifying different risks at the high risk 
end of the spectrum, and I know there are different 
levels of risk in the high risk end, although I am not 
making the most sensible decisions I think I am at the 
lower end of the higher risk end, er.. sometimes any-
way” (Deferred, decreased risk, not on PrEP, London 
clinic, age 35-39).
Participants often described their risk reduction strategies in 
terms of the ‘rules’ that they applied to their sexual activity 
before they started using PrEP, which included condom use, 
Fig. 1  Purposeful selection 
of participants for in-depth 
interviews based on trial arm 
allocation, risk behaviour and 
adherence. *One participant 
co-enrolled and in the main 
trial analysis is treated as being 
in the deferred group as this 
was his original allocation. 
However, he is treated as being 
in the immediate group here 
as that is how he was selected 
for IDI. **Additional inter-
views were conducted with a 
trans-woman, a person who 
sero-converted during the study, 
and a person who decided not to 
start PrEP
41 IDIs
Immediate = 20* Deferred = 21
RISK: Increased/high
ADHERENCE: High
9
RISK: Same/med-low
ADHERENCE: High
6
RISK: Increased/high
10
RISK: Same/med-low
9
RISK: Increased/high
ADHERENCE: Low
2
RISK: Same/med-low
ADHERENCE: Low
2
ADDITIONAL**
2
ADDITIONAL**
1
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strategic positioning, sero-sorting, avoiding ejaculate, and 
the use of PEP, as described below.
Condoms
Most participants reported using condoms inconsistently 
with rules about when and with whom to use them. Only 
four participants reported never using condoms and two 
reported consistent condom use with their main partner. 
The main reasons cited for not using condoms were that 
they reduced sexual pleasure and intimacy. A number of 
participants described how and why they had decided to not 
use condoms:
“The use of a condom is really inhibiting my sexual 
pleasure, being passive but especially being active, 
and one and a half years ago I decided to stop being 
afraid, and that doesn’t mean I am a bug chaser… I 
would like to postpone (acquiring HIV) as long as pos-
Table 1  Demographic and behaviour at enrolment
a BAME ethnicities include Pakistani, Hispanic, Arabic, mixed ethnic-
ity
b Other includes Australia, South America, South Africa and the rest 
of Europe (1 missing)
c Chemsex use includes 12 participants using GHB, 9 using meth-
edrone, and 7 using crystal meth
d PEP use excludes one missing response; six participants used PEP 
more than once
e STIs in last year excludes two missing response
Median age (interquartile range) 37.4 (31.9, 42.7)
Clinic of enrolment
London 24
Sheffield 9
Manchester 5
Brighton 3
Ethnicity
White/Irish 34
BAMEa 7
Place of birth
UK 26
Otherb 15
University degree education
Yes 25
No 16
Employed
Yes 36
No 5
In a relationship
Yes 17
No 24
Sexuality
Gay 40
Bi-sexual 1
Gender
Cis-male 40
Trans-female 1
Circumcised
Yes 10
No 31
Symptoms of depression
Yes 6
No 35
Chemsex use in the past 3 months
Yesc 13
No 28
PEP use in last yeard
Yes 14
No 26
Self-reported STI in last yeare
Yes 18
No 21
Table 2  Sexual behaviour in last 90 days, reported at enrolment
Median number of anal sex partners (interquartile range) 10 (3, 20)
Had anal sex with a new partner
Yes 35
No 6
Been passive partner
Yes 39
No 2
Been passive partner and condomless
Yes 37
No 4
Been passive during condomless sex with HIV positive 
man
Yes 14
No 27
Been passive during condomless sex with HIV positive 
man who you didn’t know was on treatment
Yes 1
No 40
Been active partner
Yes 40
No 1
Been active partner and condomless
Yes 40
No 1
Been active during condomless sex with HIV positive man
Yes 20
No 21
Been active during condomless sex with HIV positive man 
who you didn’t know was on treatment
Yes 2
No 39
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sible, but what I absolutely want is not to be afraid 
anymore… you may think well why are you doing this, 
well because it is impacting how I experience sex and 
how I experience my sexuality” (Deferred, decreased 
risk, not on PrEP, London clinic, age 35-39).
Strategic Positioning
Participants were aware of strategic positioning as a risk 
reduction strategy in terms of receptive anal sex carrying 
more risk of infection than insertive anal sex. Most partici-
pants reported being versatile in their sexual positioning, 
thereby reporting being both receptive (passive) and inser-
tive (active) during sex largely depending on the type of 
partner they were having sex with. Many applied their own 
‘rules’ to when they would be the active or passive partner 
during sex, for example only being receptive in a relation-
ship or not being receptive during condomless sex. However, 
there were frequent examples of participants not applying 
their own ‘rules’ particularly when under the influence of 
alcohol or drugs:
“I wouldn’t be passive for anyone, and this was obvi-
ously when I was compos mentis, because obviously 
when I was pissed or on a rare occasion, I would you 
know just be passive” (Deferred, low risk, on PrEP, out 
of London clinic, age 25-29).
Sero‑Sorting
Most participants discussed HIV status with potential part-
ners before sex or viewed the HIV status of potential partners 
online if meeting via sexual networking apps. The majority 
were aware that viral suppression reduced the risk of HIV 
transmission. Only one participant exclusively selected 
negative partners on dating sites. A handful of participants 
reported exclusively having condomless sex with HIV posi-
tive men who had undetectable viral loads. However, the 
limitation of sero-sorting as a HIV prevention strategy was 
acknowledged whereby a positive person may be undiag-
nosed, may not be truthful about their status, or may not be 
sufficiently adherent to treatment to remain undetectable:
“I tend to only play bareback with undetectable guys 
who I know are kind of trustworthy and taking their 
medications, they aren’t absolute drug heads who go 
on benders for weekends and don’t take their meds” 
(Deferred, increased risk, on PrEP, London clinic, age 
25-29).
Ejaculation
About half a dozen participants mentioned rules around 
ejaculation as part of their risk reduction strategies, for 
example not ejaculating or receiving ejaculate during con-
domless sex, or only doing so within a relationship.
Post Exposure Prophylaxis (PEP)
Almost half of the participants interviewed reported using 
PEP before the study. A couple of participants described 
accessing PEP after being raped and a couple after 
unplanned potential exposure with positive partners. How-
ever, besides these clear cases it appeared that participants’ 
decisions to access PEP were not consistent given equiva-
lent risks. Some participants acknowledged that there were 
multiple occasions when they should have probably accessed 
PEP but did not. A few participants described how they 
didn’t access PEP due to a sense of guilt and shame:
“Some of the PEPs were coming close to each other 
and there were times that I should have been com-
ing in but was too embarrassed because I had it quite 
recently” (Immediate, high adherence, decreased risk, 
on PrEP, London clinic, age 40-49).
Only one participant described feeling ‘judged’ by health 
care workers when trying to access PEP:
“One member of staff said to me at one point ‘Well you 
say all these things, these wonderful things, but then 
you end up back and doing it again’ … that’s when you 
think that you can’t go back” (Deferred, high risk, on 
PrEP, out of London clinic, age 35-39).
Many participants who hadn’t used PEP, described circum-
stances where they probably should have accessed it and 
would have met the eligibility criteria for it. Participants 
clearly only perceived PEP as an emergency response to a 
specific incident and not as a regular HIV prevention option.
Limited Risk Reduction
Not surprisingly, not everyone applied ‘rules’ to their sexual 
activity and many struggled to apply the rules they had set 
for their own behaviour. For some, the decision on whether 
or not to use a condom with a new partner sometimes relied 
on instinct:
“It depends on how you have met them and how they 
come across and you just go with your gut on that” 
(Deferred, increased risk, on PrEP, London clinic, age 
35-39).
For others, the decision of whether or not to use a condom 
largely relied on trust, even with casual sexual partners. This 
seemed to mainly emerge in the interviews outside of Lon-
don and Brighton, whereby participants tended to trust that 
the ‘friends’ who they had regular casual sex with, would not 
put them at risk and therefore expected them to use condoms 
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with ‘other’ partners. As such they considered their friends 
a safe group with whom to have condomless sex and in a 
few cases, were genuinely surprised when they contracted 
an STI from them.
Contexts of Risk Taking
Most participants described their risk taking within social, 
cultural and environmental contexts of the ‘gay scene’. 
When describing the contexts within which they took risks, 
we identified three key themes, that of risks associated with 
the sexualised use of recreational drugs (defined as the use 
of illicit drugs just before or during sexual activity), risks 
associated with certain geographical spaces, and the use of 
sexual networking apps as a means to access sex and risk 
taking. In addition, participants described psychological fac-
tors associated with sexual risk. We present each of these 
contexts below.
Sexualised Use of Recreational Drugs
The sexualised use of recreational drugs was a common 
theme when discussing the various contexts within which 
risk taking occurred. This was commonly referred to as 
‘chemsex’ which is a colloquial term for the use of GHB/
GBL (commonly called G), crystal methamphetamine (com-
monly called T or tina), or Mephedrone (commonly called 
meow meow or M-cat) before and during sex. Some partici-
pants also talked about using Ketamine during sex.
Almost half of the participants interviewed reported 
engaging in chemsex and described the experience as 
increasing sexual desire and a fixation on sexual fulfil-
ment, increasing sexual disinhibition, and intensifying the 
sexual experience. All participants who engaged in chemsex 
described increased risk taking in this context:
“The drug that has made the biggest difference to my 
sexual behaviour is mephedrone… It’s a cheap drug 
which has become more readily available around Lon-
don over the last couple of years and I have noticed 
that for me it has a high association with bad methods 
of protection whereby I will do much more reckless 
things … I would identify that for me, as a particular 
drug associated with chemsex and high-risk behav-
iour” (Immediate, high adherence, low risk, on PrEP, 
London clinic, age 45-49).
Geographic Spaces
Cities like London, Brighton and Manchester, where most 
of the participants lived, were frequently described as being 
‘risky’ on the basis of higher HIV prevalence, accessibility 
of gay venues, a shift in social norms related to condoms, 
and as the epicentres of the growing urban chemsex gay 
scene. It is not practical to compare participant experiences 
between the London, Brighton, Manchester and Sheffield 
clinics due to the small numbers interviewed outside of Lon-
don. However, there was a sense in the Sheffield interviews 
that participants’ risk taking was lower than described in the 
interviews conducted in other cities. This seemed to partly 
relate to different social norms relating to the acceptable 
level of risk taking and to the prominence of chemsex on 
the gay scene. 
“I have moved to Brighton from a different part of 
the country. I have had a bit of a culture shock. There 
have been times that I have actually felt that I almost 
needed to get away from Brighton because it seems 
to be a bit of a hot bed of unprotected sex, substance 
abuse and I know that it is a bit of a HIV hotspot” 
(Deferred, increased risk, on PrEP, out of London 
clinic, age 35-39).
Sexual Networking Apps
Similarly, the socio-cultural environment of sexual network-
ing applications such as Grindr, Gaydar, Scruff, BBRT and 
RECON, was described as fuelling both sexual contacts, 
identification of partners for condomless sex, and access to 
drugs and sex parties:
“If you log onto Grindr, you look through these things 
and there are quite a few instances which I feel like I 
see more often more recently …. Of people talking 
about meth and group sessions and G and all this kind 
of stuff “(Deferred, increased risk, on PrEP, London 
clinic, age 20-24).
Psychological Factors
In the interviews, about a quarter of participants specifically 
linked problematic psychological factors to their risk tak-
ing. These factors included post-traumatic stress, bereave-
ment, psychological breakdowns, relationship breakups, and 
a history of depression and anxiety. In a number of cases, 
psychological problems fuelled, and were fuelled by, both 
chemsex and sexual networking apps:
“For 20 plus years I had perfect adherence to condoms. 
Then about 4 or 5 years ago there were two things 
that happened, well three really. Firstly, I noticed that 
sexual behaviours were changing around me with far 
less condom use… real generational issue… Secondly, 
I went through a number of bereavements and started 
experiencing depression. This impacted on my sex-
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ual behaviour and I started having more unsafe sex. 
Thirdly, I started using drugs. So, it was all those three 
things that resulted in me having unsafe sex and seek-
ing out the PROUD study” (Immediate, high adher-
ence, low risk, on PrEP, London clinic, age 45-49).
Impact of PrEP on Sexual Behaviour
By the time of the in-depth interviews, 33 participants were 
or had been using PrEP. We asked participants directly 
whether they had changed their sexual behaviour since using 
PrEP, as well as comparing the sexual behaviour that partici-
pants described before and after starting PrEP.
Participants described the ways in which starting PrEP 
had impacted on their sexual behaviour along a continuum 
from changes being part of general fluctuations in behav-
iour, to reporting noticeable changes in their behaviour since 
starting PrEP, to not changing their existing behaviours. We 
present data on these three categorisations below.
Fluctuating Patterns of Sexual Behaviour
Most participants described fluctuating patterns of sexual 
risk taking over the course of their lives. The patterns were 
influenced by age, stage of life (for example when in uni-
versity), movement to a new job, home or city, changes in 
relationship status with the end of relationships often trig-
gering peaks in risk taking, social movement in and out of 
higher risk sex scenes such as the chemsex scene, as well as 
changes due to psychological factors.
In this context of fluctuating patterns of risk, a number 
of participants had recognised changes in their behaviour 
but were unsure if the changes merely coincided with them 
starting PrEP:
“Since I started PrEP, this is a complete coincidence, 
my sexual life had died off a bit, I’d been through a bit 
of a depression for the last couple of years, nothing to 
do with the PrEP it’s just my life had taken a few turns 
for the worse basically and so sexual relations had died 
off for me” (Immediate, low adherence, high risk, on 
PrEP, out of London clinic, age 30-34).
“This is the really bizarre thing, whereas I was being 
passive very often with a number of people who were 
acquaintances … but since PrEP I have actually only 
been passive with one person in the last year, on mul-
tiple occasions but even so I thought with PrEP oh 
yes I’ll be able to have sex as much as I want now but 
it’s not kind of logical like that, I just started taking 
it at a time when I was taking a lot of risks, and my 
life for whatever reason has gone down a less risky 
path… I’ve bottomed less, and with less partners” 
(Deferred, low risk, on PrEP, out of London clinic, 
age 25-29).
Other examples of initial unexpected decreases in sexual 
risk behaviour appeared to be more directly in response to 
starting PrEP:
“At first, I think I stopped having sex, I can’t quite 
explain that. When I first started taking PrEP it was a 
couple of months before I really had anything penetra-
tive… it might be coincidence… I think part of it was 
being a bit over aware of my behaviour and whether it 
was going to change… and it could just be that I was 
getting paranoid… as time passed I was clearly less 
worried about condom use… they were never great 
for me, but I used them intermittently” (Immediate, 
high adherence, high risk, on PrEP, London clinic, age 
40-44).
Conversely a few other participants described spikes in risk 
taking when they started PrEP, which dissipated over time 
as their personal circumstances and relationships changed, 
sometimes linked to drug use as in this quote:
“At some subconscious level, I think it’s supporting me 
to get to that relationship, and the unprotected sex went 
down after it spiked… it all spiked and then suddenly 
it tailed off, I had this relationship and it’s not really 
spiked back up since. I’ve not used drugs for about 
five months now” (Deferred, high risk, on PrEP, out 
of London clinic, age 20-24).
There were other examples of the peaks and troughs of 
sexual activity, such as this participant whose risk taking 
was very low when he started PrEP due to entering a new 
relationship, very high when the relationship ended, and by 
the time of the interview had returned to what it was prior 
to starting PrEP:
“There used to be a point where… somebody was like 
‘oh we are going to have safe sex’ and I was like ‘no 
I don’t want it’… whereas now I’d be thinking yeah 
okay that’s totally fine, because I want to meet some-
body where you start, and you have the discussions 
and you have safe sex and then through time … if you 
want to have unprotected sex … that they know …I’m 
negative and… that this is somebody who is maybe 
responsible and they want a long term relationship” 
(Deferred, increased risk, on PrEP, London clinic, age 
25-29).
While most participants perceived PrEP as a temporary risk 
reduction strategy for periods in their life of heightened risk, 
a couple of participants described it in the context of an 
immediate release from an overwhelming need for sexual 
freedom:
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“I was in an awful place and I just felt like I was hold-
ing the lid on a boiling pot of water so hard that I just 
couldn’t hold it anymore (trying to avoid sex with-
out condoms)… so I started on PrEP in the middle of 
March … and in that time … I feel like I have come 
full circle, I feel like I have slowly released that pres-
sure on that pot of water to the point that it’s OK now, 
it is just simmering it’s fine, I have had all my release 
that I needed to and I have almost come full circle 
that I don’t feel that strange obsessional necessity for 
bareback sex like I was before” (Deferred, increased 
risk, on PrEP, London clinic, age 25-29).
Changes in Sexual Behaviour Since Using PrEP
Overall, approximately half of all participants who had used 
PrEP described ways in which they had changed their sexual 
behaviour since using PrEP. Some participants described 
how they had previously struggled to use condoms, and 
therefore the desire to reduce condom use precipitated their 
use of PrEP:
“It is a question of pushing against an open door, 
clearly I wanted to participate in unsafe sex and obvi-
ously because of the risk I have had some resistance 
to unsafe sex, obviously not entirely 100%. But in 
taking the medication the levels of anxiety over that 
diminished. So where I may have hesitated previously, 
I dont hesitate any further…. But even now there is a 
bounded risk analysis” (Immediate, high adherence, 
increased risk, on PrEP, London clinic, age 50-54).
In the majority of cases participants added PrEP to their 
existing set of rules and PrEP influenced these rules in com-
plex and often subtle ways. For some participants, using 
PrEP meant that they reduced their use of condoms or 
changed their rules about when to use condoms:
“There is no doubt that I have also had more unpro-
tected sex than before, for sure…it doesn’t mean that I 
only have unprotected sex, but it does mean that I have 
more… it is probably 80% more, much more than pro-
tected” (Deferred, high risk, on PrEP, out of London 
clinic, age 45-49).
“I felt like it gave me the green card to do whatever the 
hell I wanted…I don’t use condoms at all any more. 
I’m starting to notice that its actually bad where, not 
that I’m encouraging people to not use condoms with 
me, but it’s like if I’m going to be a top there is no 
point in me wearing a condom, because I just can’t 
do it anymore, it won’t work so if they want to have 
sex with me, then it’s a level of risk that they have to 
accept and I won’t push it on them, but I can’t do it 
anymore (use condoms). And I don’t know whether I 
like that development” (Immediate, high adherence, 
high risk, on PrEP, London clinic, age 30-34).
As with the last sentence in the quote above, a few partici-
pants were not comfortable with their reduced condom use. 
However, this discomfort was not about the risk of STIs but 
seemed to be solely related to social norms about condom 
use for gay men. The following quote is another example of 
this discomfort when asked by the interviewer “Have any of 
your decisions around sex changed?”
“Yes I would say so and I am not always convinced it 
has been for the better… So there have been a couple 
of occasions where I haven’t used condoms with com-
pletely random one-off partners … when I have felt 
pretty shitty for some reason or another, and I have 
acted out sexually” (Immediate, low adherence, low 
risk, on PrEP, London clinic, age 30-34).
Other participants reported the main benefit of using 
PrEP was the opportunity to stop using condoms with HIV 
positive partners within relationships, despite understanding 
the evidence related to an undetectable viral load:
“I have a partner that is HIV positive, we have gone 
without condoms since being on the study, which we 
wouldn’t do before” (Immediate, high adherence, 
increased risk, on PrEP, London clinic, age 35-39).
“We don’t use condoms since I’ve been on PrEP… he’s 
undetectable anyway and with me being on PrEP, so 
no we don’t use condoms anymore… that is something 
we still don’t do, we don’t cum in one another, it would 
just seem silly given the circumstances” (Immediate, 
high adherence, low risk, on PrEP, out of London 
clinic, age 40-44).
For some participants PrEP use influenced the ‘rules’ that 
they had previously applied to their sexual activity in terms 
of sero-sorting and strategic positioning:
“It has definitely made me more likely to take risks, 
definitely I must admit, as I don’t tend to worry about 
what the status of the person is … now” (before PrEP, 
sero-sorted for negative partners and never used con-
doms) (Deferred, decreased risk, on PrEP, out of Lon-
don clinic, age 35-39).
“I have always been more top, however it is true 
that I have definitely experienced more as a bottom 
since (PrEP)… now I am more relaxed about letting a 
guy fuck me, I just don’t desire it that much, it takes 
a special kind of person to make me want to do it” 
(Deferred, high risk, on PrEP, out of London clinic, 
age 40-44).
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Although some participants did not think that PrEP had 
influenced their behaviour, they described sex they were not 
sure they would have had without PrEP:
“I have a friend … we are effectively dating but there 
has been no attempt at a long-distance relationship. We 
use condoms but at the end of this trip … I was like, 
okay I know you have been tested recently, I know you 
have been on PrEP as well… and I thought I see you 
so rarely it would be fun to have unprotected sex… I 
knew it was a risk and at the end of the three weeks 
I thought I’m going to have unprotected sex with this 
guy and I did … I can’t remember any other occur-
rence where I made an active decision” (Deferred, low 
risk, on PrEP, out of London clinic, age 25-29).
Consistent Sexual Behaviour Before and After PrEP
While approximately half of participants reported changing 
their sexual behaviour since starting PrEP, the other half 
firmly believed that using PrEP had not altered their sexual 
behaviour.
“I haven’t changed the way I think because I am taking 
this pill… having these pills doesn’t give me an excuse 
to be more crazy than I already am” (Immediate, high 
adherence, increased risk, on PrEP, London clinic, age 
35-39).
For most of the participants who didn’t change their behav-
iour, PrEP was the ‘additional’ protection that they added 
to their existing risk reduction strategies in an attempt to 
minimise the risk of HIV acquisition while having the sex 
that they desired:
“I’ve taken the medication and obviously I’ve still had 
intercourse in the way that I would if I’ve not taken the 
tablet really, so it’s not done anything with the behav-
iour side of it, my behaviours have remained the same 
throughout the full 24 months of me taking the tablet, 
I’d still behave in the way that I would” (estimates 
he has condomless sex with about 10% of partners) 
(Immediate, high adherence, low risk, on PrEP, out of 
London clinic, age 20-24).
In some cases, participants reported that their risk taking 
was already substantial and therefore did not increase after 
starting PrEP:
“I was having a huge amount of condomless sex before 
PrEP… I am not going to not bareback and always use 
condoms” (Immediate, high adherence, decreased risk, 
on PrEP, London clinic, age 45-49).
For others, their risk taking was relatively low before they 
started using PrEP and it remained so:
“I have a partner who is positive… and undetectable… 
prior to going onto this programme anyway we had 
been having unprotected sex, so for me it is more a belt 
and braces thing” (Deferred, low risk, stopped PrEP, 
London clinic, age 50-54).
It is also worth pointing out that many of the interviews 
occurred before the release of the PROUD results. As such, 
while most participants were using PrEP on the basis of 
knowing that it reduced the risk of HIV, there is a chance 
that a few participants continued to circumscribe their 
behaviour within the context of a ‘trial’.
“I don’t know if it works, I’m hoping it does, but I’m 
not going to change and be more reckless because of 
it” (Immediate, low adherence, high risk, on PrEP, out 
of London clinic, age 30-34).
“If you said Truvada was 100% effective, I would 
abandon condom usage I think because as I said all 
of the other STIs are treatable” (condom use reduced 
after starting PrEP) (Deferred, high risk, on PrEP, out 
of London clinic, age 45-49).
In relation to this last quote, it was clear throughout the 
interviews that participants were concerned about HIV but 
largely viewed STIs as a treatable problem. A few partici-
pants were particularly concerned about Hep C mainly in 
relation to fisting and sex toys, but in the main the aim was 
to avoid the risk of HIV acquisition with little concern for 
other STIs. Considering this, it was noteworthy that in the 
majority of the interviews participants still referred to sex on 
PrEP without a condom as ‘unprotected’ sex and therefore 
did not change their language in terms of defining this as 
condomless sex protected by PrEP, at least in terms of HIV.
Discussion
This is the first paper to qualitatively explore the impact of 
PrEP use on the sexual behaviour of gay, bisexual and other 
MSM in the UK. It contributes to a growing literature of the 
experiences of ‘first wave’ PrEP users [14]. By exploring 
the background context of sexual risk taking, we are able 
to describe the diverse ways in which the initiation of PrEP 
use influences sexual behaviour and risk management strat-
egies. The findings highlight that in the main, individuals 
who were already having frequent condomless sex, added 
PrEP to the existing range of risk management strategies, 
influencing the boundaries of the ‘rules’ for some but not 
all. While approximately half the participants reduced other 
risk reduction strategies after starting PrEP, the other half 
did not alter their behaviours. PrEP provided an additional 
HIV prevention option to a cohort of GBMSM at high risk 
of HIV due to inconsistent use of other prevention options.
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This analysis highlights the complexities and changing 
dynamics of sexual risk behaviours for GBMSM in urban 
centres in England. PROUD participants self-identified as 
‘at risk’ individuals and were all having condomless sex 
to varying degrees. Most participants attempted to manage 
their risk of HIV through an imperfect combination of risk 
reduction strategies including decisions around condom use, 
strategic positioning, sero-sorting, ejaculation and PEP use. 
This evidence is consistent with the quantitative findings 
from PROUD as well as qualitative findings from other PrEP 
studies in the USA [12, 15, 16]. All participants interviewed 
acknowledged that their existing risk management strategies 
were insufficient and therefore sought out PrEP as an addi-
tional risk management option.
Participants described their sexual risk taking before ini-
tiating PrEP in the context of the sexualised use of drugs, 
geographical spaces linked with higher risk sexual norms, 
and digitised sexual networking. In a recent qualitative study 
in England, newly diagnosed MSM identified these same 
three factors, drug use, geographical space and digital net-
working, as part of a complex web of factors that influenced 
their risk behaviours and HIV acquisition [17]. There is a 
growing body of evidence on the sexualised use of drugs in 
the UK and associations with higher risk sexual behaviours 
including condomless sex, multiple partners and group sex 
[18–23]. Indeed, in a European wide survey of MSM, Lon-
don, Brighton and Manchester were the three cities with the 
highest rates of recent chemsex use (13.2–16.3%) [24]. In 
PROUD, 44% (231/525) of participants reported using any 
of the three drugs most commonly associated with chemsex 
in the three months prior to enrolment [12]. In the IPER-
GAY study in France, 29% (95/331) of participants reported 
chemsex and interestingly chemsex users were twice as 
likely to use PrEP the last time they had sex than non-users 
[25]. Evidence from both trials, and from a recent evaluation 
of PrEP use among chemsex users in Australia, suggests that 
MSM engaging in chemsex are incorporating PrEP into their 
sexual practice [26, 27]. PrEP, particularly event-based dos-
ing, could play an important role in reducing the risk of HIV 
during periods in peoples’ lives when they are engaging in 
chemsex and related higher risk behaviours.
About a quarter of participants described their risk tak-
ing in the context of psychological factors. Problematic 
psychological factors are known to influence sexual risk-
taking behaviour and individual’s ability to mitigate risk 
[28]. Psychological traumas are known to be an element 
of the multiple interrelated structural, social and biologi-
cal factors that underpin risk taking [29]. Childhood and 
adult experiences of life stressors, trauma or discrimina-
tion have been shown to influence risk taking and HIV 
acquisition [17]. Indeed, in iPrEX, they observed an asso-
ciation between depression and higher risk sexual behav-
iour and specifically recommended the continued use of 
PrEP during periods of depression [30]. PrEP appears to 
offer an important layer of protection from higher risk sex 
during periods of depression or psychological stress.
In this study, the impact of PrEP on sexual behaviour 
was diverse, having a substantial impact on sexual behav-
iour for some participants and no or limited impact for oth-
ers. The reality for most participants was that the incon-
sistency of their condom use in higher risk sexual contexts 
meant that PrEP was an important addition irrespective of 
the shifts in other prevention strategies. These qualitative 
data provide a more in-depth view of the nuances of sexual 
risk behaviour and the dynamic and fluid nature of risk, 
that was impacted by individual, inter-relational, social, 
cultural and psychological factors for many. Despite the 
continued focus on the potential public health harm of 
‘risk compensation’ among this cohort of GBMSM, PrEP 
offered substantial protection against HIV as the biggest 
risk that they face in terms of sexual wellbeing and few 
participants prioritised protection from STIs to the same 
extent.
Evidence on the impact of PrEP on sexual behaviour is 
beginning to emerge although without a control group in a 
randomised control trial, it is difficult to measure impact 
during implementation programmes. Much of the quanti-
tative research suggests few changes in sexual behaviour 
among PrEP users. For example, a systematic review and 
meta-analysis of data from 18 PrEP studies consistently 
found no reported decrease in condom use among partici-
pants using PrEP and with the exception of one trial, no 
reported increase in the number of sexual partners [31]. 
Similarly, in a wait-listed trial design in the USA, there were 
no differences in sexual behaviour between the PrEP and 
no-PrEP group, nor after initiation of PrEP in the deferred 
group [32]. A review of counselling notes in a PrEP clinic 
in San Francisco found that clients rarely reported changing 
existing sexual behaviours and in the main included PrEP 
in their existing HIV prevention strategies, which as in this 
paper, included intermittent condom use and sero-sorting 
[33]. In a qualitative study in the USA, while some partici-
pants acknowledged engaging in sexual encounters that they 
may have avoided prior to using PrEP, most incorporated 
PrEP into existing practice [15]. Similarly, in the iPrEX open 
label qualitative study, most participants did not substan-
tially change their behaviour and the changes that did occur 
were usually fluid [16]. However, data from the open-label 
phase of IPERGAY and two PrEP implementation sites in 
San Francisco suggest decreases in condom use, although 
there is no evidence of an increase in STIs [34–37].
The strength of this analysis is that we collected quali-
tative data from individuals who were using PrEP in a 
randomised open-label study to reduce their risk of HIV 
acquisition. The fact that the qualitative data collection was 
integrated within the trial protocol, selection of interviewees 
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was purposeful and derived from the self-reported quantita-
tive data are also strengths of this study. The limitations are 
that the individuals in PROUD were a particularly high-risk 
group and clearly acknowledged their risk behaviours and as 
such may not be representative of all GBMSM in England 
who are seeking PrEP. Similarly, participants in PROUD 
were already inconsistent condom users, and therefore these 
findings do not address the impact of PrEP on condom use 
among GBMSM who consistently use condoms. In addi-
tion, the PROUD cohort were in the main highly educated, 
employed and predominantly white GBMSM, and therefore 
further research is required in order to speak to the needs of 
less privileged and marginalised groups of GBMSM as well 
as trans women [12]. Also of note, trans men were excluded 
from this study and are likely to have very different experi-
ences of risk management. While the purposeful sampling 
approach had strengths in terms of allowing us to identify 
individuals based on their risk and adherence behaviour, it 
also had limitations as it meant we only selected participants 
who were completing the self-reported sexual behaviour 
questionnaire and therefore were most engaged in the study. 
As with all qualitative data, these data are subject to social 
desirability bias, although the descriptions of sexual risk 
taking in the interviews would suggest limited censoring 
of reporting risk behaviours. In this paper, we have focused 
exclusively on the impact of PrEP on sexual behaviour and 
this has enabled us to explore this topic in-depth. However, 
due to paper length we have been unable to describe par-
ticipants’ experiences of using PrEP and the psychosocial 
benefits it offered. These data will be presented in separate 
papers.
In summary, PrEP provides a critical and necessary 
additional HIV prevention option that individuals can add 
to existing strategies in order to enhance protection, at least 
from HIV. As a daily pill, PrEP offers protection in the 
context of sex cultures associated with the sexualised use 
of drugs, digitised sexual applications and shifting social 
norms around sexual fulfilment and risk taking. PrEP can 
offer short or longer-term options for individuals as their 
sexual desires change over their life course offering pro-
tection from HIV during periods of heightened risk. PrEP 
should not be perceived or positioned in opposition to the 
existing HIV prevention toolkit, but rather as additive and 
as a tool that can and is having a substantial impact on HIV.
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